Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Study to Evaluate the Safety and Immunogenicity of NDV-3 Formulated With or Without Alum (AlOH) and Administered Either Intramuscular (IM) or Intradermally (ID) to Healthy Adults

NCT01447407 is registered in ClinicalTrials.gov with NovaDigm Therapeutics, Inc. as lead sponsor.

NCT NCT01447407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01447407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Study to Evaluate the Safety and Immunogenicity of NDV-3 Formulated With or Without Alum (AlOH) and Administered Either Intramuscular (IM) or Intradermally (ID) to Healthy Adults
Lead sponsor
NovaDigm Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2011
Completion date
December 31, 2012
Enrollment
164 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

candidiasis, staphylococcal infections, yeast infections